Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

Autor Li, Shuyu D., Martial, Annia, Schrock, Alexa B., Liu, Jane J.
Vydáno v Exp Hematol Oncol (2017)

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

Autor Ayers, Kristin L., Ma, Meng, Debussche, Gaspard, Corrigan, David, McCafferty, Jonathan, Lee, Kyeryoung, Newman, Scott, Zhou, Xiang, Hirsch, Fred R., Mack, Philip C., Liu, Jane J., Schadt, Eric E., Chen, Rong, Li, Shuyu D.
Vydáno v BMC Cancer (2021)

A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab Combined with Alemtuzumab as Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Older Patients:...

Autor Zent, Clive S., Wang, Xin Victoria, Ketterling, Rhett P., Hanson, Curtis A., Libby, Edward N., Barrientos, Jacqueline C., Call, Timothy G., Chang, Julie E., Liu, Jane J., Calvo, Alejandro R., Lazarus, Hillard M., Rowe, Jacob M., Luger, Selina M., Litzow, Mark R., Tallman, Martin S.
Vydáno v Am J Hematol (2016)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Sma...

Autor Ayers, Kristin L., Mullaney, Tommy, Zhou, Xiang, Liu, Jane J., Lee, Kyeryoung, Ma, Meng, Jones, Scott, Li, Li, Redfern, Arielle, Jappe, Whitney, Liu, Zongzhi, Goldsweig, Howard, Yadav, Kamlesh K., Hahner, Nicholas, Dietz, Matthew, Zimmerman, Michelle, Prentice, Tony, Newman, Scott, Veluswamy, Rajwanth, Wisnivesky, Juan, Hirsch, Fred R., Oh, William K., Li, Shuyu D., Schadt, Eric E., Chen, Rong
Vydáno v Oncologist (2021)